Streetbeat News

Regulatory

FXI

GLD

China's central bank has issued gold import quotas to several banks after a temporary pause, according to Reuters. This move is expected to impact the gold market and related financial sectors.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 2:15 pm

EIS

SPY

A joint statement from Qatar, the US, and Egypt indicates that a US proposal builds on recent agreements and aims to close gaps for rapid implementation.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 2:05 pm

SCPX

Scorpius Holdings has announced a new pricing of a $12.5 million underwritten public offering, consisting of 12.5 million shares of common stock or pre-funded warrants. The company also has a 45-day option to purchase an additional 1.875 million shares. Additionally, Scorpius Holdings has received approval for a financial viability exception from the NYSE American.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 1:51 pm

EBS

GOVX

Shares of vaccine and mpox-related stocks are trading higher after the WHO declared it a global health emergency.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 1:38 pm

FEXD

Fintech Ecosystem Development (FEXD) announced it cannot complete its initial business combination within the required time period. As a result, the company will redeem all outstanding shares of Class A common stock from its IPO at a per-share price of approximately $10.69.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 1:35 pm

INCY

Incyte Corporation (NASDAQ: INCY) released promising topline results from its Phase 3 inMIND trial for Monjuvi (tafasitamab) in combination with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma. The trial met its primary and key secondary endpoints, showing no new safety signals. Incyte plans to file a supplemental marketing application by the end of the year.

Portfolio Pulse from Vandana Singh

August 16, 2024 | 1:29 pm

BNTX

MRNA

PFE

Pfizer and BioNTech's combined COVID-19/flu vaccine failed to meet one of its primary goals in a Phase 3 trial, showing lower efficacy against influenza B. The companies are evaluating adjustments to improve the vaccine. Moderna's similar vaccine showed positive results in June. Pfizer's stock is down 0.03% and BioNTech's is down 3.72% in premarket trading.

Portfolio Pulse from Vandana Singh

August 16, 2024 | 1:19 pm

CING

Cingulate shares are trading higher after the company was granted European patent No. 3261625 for CTx-1301, its lead asset for the treatment of ADHD.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 1:18 pm

TGL

Treasure Global has submitted a request to withdraw its S-1 registration statement.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 1:02 pm

OCTO

Trading halt status was updated at 8:55:00 AM ET, indicating a quotation resumption. The news and resumption times are provided.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2024 | 12:55 pm